Indigenous Ghanaian company, Intravenous Infusions PLC (IIPLC), will take its turn on the Ghana Stock Exchange (GSE)’s “Facts Behind the Figures” programme on Wednesday, August 14, to present company’s performance and plans to stakeholders. The last time IIPLC was on the platform was in 2022 as the country was easing back from a global pandemic.

IIPLC is the leading manufacturer of Intravenous (IV) fluids in Ghana and West Africa. Founded in 1969 and begun operations in 1974 as the first pharmaceutical company producing intravenous infusions in Ghana. The company is located in Koforidua with a staff strength of over 150 employees. According to IIPLC’s unaudited financial statement for the first half of 2024, it made a total revenue of GH¢12,614,849 as at June 30 against GH¢13,570,159 in the same period the previous year with year-on-year change of -7%. Its operating profit in H1 2024 stands at GH¢980,658 against GH¢2,706,911 in 2023. The Facts Behind the Figures programme would afford IIPLC the opportunity to explain the company’s performance to brokers, investors and the media while stating across the company’s plans for the future.

This programme is strictly by invitation.